| BACKGROUND
Graves' orbitopathy (GO) is an orbital inflammatory condition associated with circulating anti-TSH receptor antibodies (TRAb). Clinically significant GO is present in about 25% of those diagnosed with Graves' disease (GD) 1 and, in the majority of cases, develops following thyroid dysfunction. 2 Over an 18 month period, of those with GD without GO at baseline, approximately 13% can be expected to develop GO. 1 In the most severe cases, GO can be sight-threatening. However, even mild GO can cause significant ocular symptoms, which can have a negative impact on quality of life. 3, 4 At any one time, there is a group of patients with GD attending endocrine clinics with subtle symptoms and signs of GO, which are easily overlooked. A number of inexpensive interventions have been demonstrated to be safe and effective in the management of individuals with mild active GO, making early identification of cases worthwhile. These include selenium supplements, tients with GD in the UK are under the care of an endocrinologist, by making all patients with a confirmed diagnosis of GD aware that they are at risk of GO (and how to reduce the risk), we might both reduce the incidence and the time to presentation of the disease. As GO can present up to 3 years or more after the diagnosis of GD, the aim was to provide information on the early signs of GO in a form, which would be retained in an easily accessible way by patients. We therefore devised a wallet-sized "GO early warning card" describing the key symptoms of GO 13, 14 and preventive measures, as well as a named telephone contact and an Internet link to further information. The intention was that the cards would alert patients to early relevant symptoms and, using the contact number, avoid referral delays. However, as some of the early symptoms are relatively nonspecific, the concern was that distributing the cards to all patients with GD would generate patient anxiety and large numbers of inappropriate self-referrals. Here, we report a four centre study to evaluate the performance of such an "early warning card" system.
| METHODS
We designed credit card-sized GO early warning cards (Figure 1 
| RESULTS
One hundred and sixty cards were distributed in total. The age range of card recipients was 18-84 years (median age 47 years), and 123/160 (77%) card recipients were female. The median number of years since GD diagnosis for all card recipients was 2 years (range 0-30 years); 37/160 (23%) had had one or more relapses ( Table 2) .
Over twelve months, ten telephone calls from nine patients were received (one patient called twice); therefore, 6% of cards distributed resulted in telephone contact ( Figure 2 ). Nine of the ten calls received occurred within the first 3 months of the follow-up period. All ten calls related directly to ocular symptoms. One call was managed with telephone advice alone. In this case, the individual had symptoms classical of transient ischaemic attack and was advised to see their GP for further assessment. One call was initially managed with telephone advice; however, following a second call from the same individual, a clinic review was arranged. The other seven calls resulted in an additional clinic review. Of the eight patients offered clinic review, six were initially seen in an endocrinology clinic at a tertiary referral centre by a consultant or specialist registrar, and two were seen directly in a multidisciplinary thyroid-eye clinic. Two of the six patients reviewed initially in an endocrinology clinic had a diagnosis of mild, active GO and were offered further review in a specialist multidisciplinary thyroid-eye clinic. Of the two patients seen directly in the multidisciplinary thyroid-eye clinic, one was found to have mild active GO, and the other was found to have mild inactive GO. All three individuals confirmed to have active GO were offered smoking cessation advice if relevant, topical treatment and/or selenium supplements.
Therefore, in total, four diagnoses of GO were made (Table 3) . After the initial clinical review and initiation of treatment, all four patients were followed up; symptoms and signs of GO had fully resolved in 3/4 when followed up between 2 and 6 months following presentation, and significantly improved in 1/4 at 2 months' follow-up. The sensitivity of the early warning cards can be calculated at 44% (given that nine individuals telephoned, one received a diagnosis of TIA and was directed to the appropriate services, eight were reviewed in clinic and four of these had GO).
At twelve months, clinical letters for all warning card recipients were reviewed to determine what proportion had developed clinically significant GO during the follow-up period but had not reported it via the telephone helpline. In total, of the 160 individuals who had received a card, 5 had developed GO within the twelve month follow-up period but had not called the helpline ( Figure 2 ). Three individuals were noted to have minor ophthalmic abnormalities (periorbital swelling, eyelid redness, eyelid swelling) during routine endocrinology follow-up appointments at 10, 8 and 6 months following receiving an early warning card but were asymptomatic. Two individuals had developed symptoms of GO but had not telephoned to report these. One presented to their GP with eyelid swelling 3 months after receiving a warning card and was referred to the local joint thyroid-eye clinic.
The other complained of a change in the appearance of their eyes 8 months following receiving a warning card when attending their routine endocrinology outpatient follow-up and was referred to the local joint thyroid-eye clinic. Both were diagnosed with mild, active GO. on review of clinic letters, the specificity of the early warning cards can be calculated as 97%. Of the 45 responders who remembered receiving a card, eight (18%) reported that they had had eye problems of some description since receiving the card; however, only three (7%) had called the telephone number on the card during the 3-month observation period before feedback was sought. Of these, one had found the telephone consultation very helpful, one reported that it was somewhat helpful and one reported that it was not helpful as they had been unable to speak to anyone. To determine whether participants kept the cards, survey responders were asked to quote their card's unique serial number at the end of the survey, and 30/45 participants (67%) were able to do so, suggesting that most participants retained their card.
| DISCUSSION
We have found that it is practical to distribute GO early warning cards to patients in busy endocrinology clinics. Some of the endocrinology clinicians participating in the study reported that the cards acted as a prompt to discuss GO symptoms and possible prevention measures with individuals with GD. In the cohort studied, the GO early warning cards do not result in an excessive number of telephone calls, and all calls that were received were related to ocular symptoms and were therefore appropriate. The cards were appreciated by the majority of patients from whom feedback was received. Three individuals who had contacted the telephone helpline responded to the request for feedback, and one reported that they had been unable to contact someone for advice and was therefore dissatisfied. If this scheme was to be rolled out more widely, the logistics of providing a telephone helpline service would need to be clarified. For example, the card would need to stipulate when individuals could expect to speak to someone, perhaps using an answer machine service to ensure that patient expectations were met.
The majority of the telephone enquiries that were received resulted in an additional clinic review (for 8 individuals in total; 5% of those receiving a card). Depending upon the local service structure, patients were reviewed either in a specialist endocrinology clinic, by
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an endocrinologist, or in a multidisciplinary thyroid-eye clinic. In total, 1/8 had inactive GO and 3/8 had active disease and were offered treatment. At subsequent follow-up, signs and symptoms of GO had significantly improved in 1/4 and entirely resolved in 3/4 patients, suggesting that GO is often transient, as noted by others. 1 Therefore, the sensitivity of the early warning cards can be calculated at 44%
(given that nine individuals telephoned, one received a diagnosis of TIA and was directed to the appropriate services, eight were reviewed in clinic and four of these had GO). Of the 151 individuals who had not called the telephone helpline in the twelve month follow-up period, review of the clinic letters revealed that 5 had as developed signs and/or symptoms of GO; therefore, the specificity of the early warning cards can be calculated as 97%.
An ongoing study looking at the incidence of GO in individuals with recently diagnosed GD (excluding those with GO at the time of presentation with GD) has found that, over a 12 month period, 16% of individuals will develop GO (with 2% developing moderate-to-severe disease) (W. Wiersinga, personal communication, 18/4/17). In our study, this equates to 26 participants predicted to develop GO, with three of these predicted to develop moderate-to-severe GO. Tanda et al 1 followed up a large cohort of individuals with newly diagnosed GD without GO at baseline and found that, at 18 months, approximately 13% had GO, with the majority of cases being mild. In our study, this equates to 13 individuals predicted to develop GO over 12 months.
In total, we observed that 9 people developed GO over 12 months (all cases were mild), and the early warning card scheme captured 4/9
cases. The total number of cases in the cohort is less than expected, and this is likely due to the fact that a significant proportion of the cohort were follow-up patients, with a range in years from diagnosis of 0 to 30 years (median 2 years) or patients with a relapse of GD rather than newly diagnosed individuals. Including a greater number of participants at the outset of the study, or including only individuals with newly or recently diagnosed GD, would likely have resulted in a greater number of cases of GO being identified. It is also possible that if only those with newly or recently diagnosed GD were given early warning cards, that the number of telephone calls to the helpline would increase as a result of increased incidence of GO in these individuals as compared to follow-up cases. Another factor which might increase telephone contacts if this group was studied exclusively is that they have had fewer patient-physician consultations compared to follow-up patients and therefore might have more questions or concerns regarding minor ocular symptoms compared to patients who have been under clinic follow-up for longer.
The early warning card scheme enabled 4/160 patients with Graves' disease (3%) to receive an earlier diagnosis of GO; however, an additional 5 patients developed symptoms or signs of mild GO during the follow-up period but did not report these through the telephone helpline. Three of these 5 individuals were asymptomatic and noted to have minor ophthalmic abnormalities during routine endocrine follow-up appointments, which explains why they did not call the helpline. Two individuals however had developed symptoms of GO but had not telephoned to report these. Possible reasons for this include patient preference not to draw attention to their symptoms, mild symptoms not troublesome or worrying to the patient or having a follow-up appointment already scheduled meaning they would be able to report their symptoms early without the need for additional support.
In addition, as the majority of telephone calls resulting from the early warning cards were made early on (within 3 months of the cards being distributed), it is possible that the patients who developed GO but not used the helpline had forgotten about the warning cards (30/45 card recipients (67%) who responded to the request for feedback were able to correctly report the serial number on the card after 3 months confirming it was still in their possession) and that the intervention offered only short-term benefit without reinforcement. Further studies will be required to elucidate the underlying reasons. ) are most effective when administered early in the course of the disease, between 6 and 9 months from the onset of symptoms.
However, a recent UK-based study showed that the average time that it takes for patients to receive a diagnosis of GO from their first visit to any doctor with symptoms of GO is 9.37 months. 19 Many patients therefore currently miss the window for best response to medical therapies, because the diagnosis of GO is made too late.
The incidence of GO seems to be falling, and this is likely, in part, 
| CONCLUSION
Graves' orbitopathy (GO) early warning cards can be used to alert both patients with GD and the physicians caring for these individuals to the risk of GO and are well received by patients. They do not result in an excess burden of telephone contacts and resulted in early detection of GO in 45% of cases. Regular reinforcement of risk awareness may result in more cases being detected early. GO early warning cards can be successfully used to fast-track patients with GD who develop ocular symptoms to receive an earlier specialist assessment for GO and potentially an earlier diagnosis and treatment, and represent a simple and cost-effective intervention.
